Clinician Participation in CADTH’s Pan-Canadian Oncology Drug Review: Contribution and Impact on Cancer Drug Funding Recommendations

Current Oncology - Canada
doi 10.3747/co.24.3644
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

MultiMed Inc.

Related search

Informing Canada’s Cancer Drug Funding Decisions With Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review

Current Oncology
Oncology
2013English

Impact of the Pan-Canadian Pricing Alliance (Pcpa) on Access to Drug Treatment Options for Canadian Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Clinically Relevant Drug-Drug Interactions in Oncology

British Journal of Clinical Pharmacology
Pharmacology
1998English

Drug Pricing and Value in Oncology

Oncologist
Cancer ResearchMedicineOncology
2010English

The Impact of Korean Prospective Drug Utilization Review Program on the Rate of Drug-Drug Interactions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

State Drug Control and Illicit Drug Participation

1999English

Pan-Canadian Review of Cancer Drugs Will Not Be Binding on Provinces

CMAJ
Medicine
2010English

Biomarkers in Oncology Drug Development

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2008English

Systematic Review of Pharmacogenomics and Adverse Drug Reactions in Paediatric Oncology Patients

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy